SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Clinical trials for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS explained in plain language.
Never miss a new study
Get alerted when new SLE - SYSTEMIC LUPUS ERYTHEMATOSUS trials appear
Sign up with your email to follow new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Tiny early trial launches for new autoimmune drug
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug called CC312 in just 6 adults with lupus, myositis, or scleroderma that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive multip…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Engineered immune cells take on lupus and scleroderma in new trial
Disease control Recruiting nowThis early-stage study is testing a new type of cell therapy (called QT-019C) in 12 adults with severe autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. The therapy uses specially engineered immune cells from a healthy donor to target …
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Could cord blood cells tame tough lupus?
Disease control Recruiting nowThis early-stage trial tests a new treatment made from donated umbilical cord blood cells, designed to target and calm the overactive immune system in adults with severe lupus that hasn't responded to standard therapies. About 48 participants will receive the therapy to see if it…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: Chengdu Ucello Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Engineered immune cells take on lupus in new trial
Disease control Recruiting nowThis trial is testing a treatment called MB-CART19.1, which uses a patient's own immune cells that are modified in a lab to target and destroy faulty cells involved in lupus. It is for adults with severe lupus that has not improved with standard treatments. The study will first f…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1, PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New lupus drug CC312 enters first human safety trial
Disease control Recruiting nowThis early-stage study tests a new drug, CC312, in 32 adults with moderate-to-severe systemic lupus erythematosus (SLE). Participants receive either CC312 or a placebo intravenously to check for safety, side effects, and how the drug moves through the body. The goal is to see if …
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 26, 2026 17:46 UTC
-
Lupus drug belimumab may shield organs from damage, new study hopes to prove
Disease control Recruiting nowThis study is tracking 684 people with lupus to see if the drug belimumab can prevent serious organ damage (called BILAG A flares) better than standard care alone. Researchers are using real-world data from clinics in Greece, comparing patients on belimumab to those on usual trea…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Sponsor: Biomedical Research Foundation, Academy of Athens • Aim: Disease control
Last updated Jun 26, 2026 14:41 UTC